Estados financieros detallados de Olema Pharmaceuticals, Inc. (OLMA): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $9.73, OLMA presenta beneficios negativos (P/E no significativo) y un ROE del -48.22%. La capitalización bursátil es de $850M.
Cuenta de Resultados (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $8244 | $9033 | $11000 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$8244 | -$9033 | -$11000 | 0 | 0 | 0 | 0 | 0 |
| I+D | $1.7M | $3.9M | $13.7M | $51.1M | $82.3M | $86.1M | $124.5M | $157.7M |
| Generales y Administrativos | $386000 | $403000 | $7.8M | $20.4M | $24.7M | $18.8M | $17.7M | $21.0M |
| Gastos Operativos | $2.1M | $4.3M | $21.5M | $71.5M | $107.0M | $105.0M | $142.3M | $178.7M |
| Beneficio Operativo | -$2.1M | -$4.3M | -$21.5M | -$71.5M | -$107.0M | -$105.0M | -$142.3M | -$178.7M |
| EBITDA | -$2.1M | -$4.3M | -$21.5M | -$70.9M | -$104.4M | -$96.3M | -$129.1M | -$162.0M |
| Gastos por Intereses | $28000 | | $653000 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$2.2M | -$4.3M | -$22.1M | -$71.1M | -$104.8M | -$96.7M | -$129.5M | -$162.5M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$2.2M | -$4.3M | -$22.1M | -$71.1M | -$104.8M | -$96.7M | -$129.5M | -$162.5M |
| BPA | $-0.16 | $-0.11 | $-0.58 | $-1.79 | $-2.62 | $-2.14 | $-2.20 | $-1.87 |
| BPA Diluido | $-0.16 | $-0.11 | $-0.58 | $-1.79 | $-2.62 | $-2.14 | $-2.20 | $-1.87 |
| Acciones en Circulación (Diluidas) | $14.1M | $40.2M | $39.3M | $39.5M | $40.0M | $45.2M | $58.7M | $87.0M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | -$187000 | -$119000 | 0 |
| Beneficio Operativo | -$45.9M | -$50.1M | -$58.0M | -$67.2M |
| EBITDA | -$42.2M | -$45.9M | -$53.0M | -$63.0M |
| Beneficio Neto | -$42.2M | -$46.1M | -$53.1M | -$63.2M |
| BPA | $-0.49 | $-0.50 | $-0.52 | $-0.61 |
| BPA Diluido | $-0.49 | $-0.51 | $-0.52 | $-0.61 |
Balance (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $3.1M | $68000 | $338.5M | $13.8M | $23.7M | $68.5M | $139.5M | $48.3M |
| Inversiones a Corto | 0 | 0 | 0 | $273.4M | $180.7M | $193.3M | $294.6M | $457.1M |
| Cuentas por Cobrar | 0 | 0 | 0 | $130000 | $319000 | $673000 | $2.1M | $4.1M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $3.2M | $103000 | $342.1M | $290.7M | $208.9M | $266.5M | $438.5M | $515.5M |
| Inmovilizado Material | $26000 | $26000 | $75000 | $4.7M | $4.0M | $3.3M | $2.1M | $1.1M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | $683000 | 0 |
| Activos Totales | $3.3M | $132000 | $342.7M | $295.9M | $215.6M | $276.9M | $451.0M | $533.4M |
| Cuentas por Pagar | $116000 | $935000 | $719000 | $23000 | $374000 | $2.7M | $4.5M | $9.3M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | $1.2M | $1.1M |
| Pasivos Corrientes | $201000 | $1.4M | $4.6M | $9.0M | $16.5M | $21.6M | $41.8M | $51.8M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $69000 |
| Pasivos Totales | $9.5M | $10.7M | $4.6M | $11.4M | $18.1M | $23.1M | $42.0M | $54.9M |
| Reservas | -$6.4M | -$10.8M | -$33.1M | -$104.2M | -$209.0M | -$305.6M | -$435.1M | -$597.6M |
| Patrimonio Neto | -$6.3M | -$10.6M | $338.1M | $284.6M | $197.5M | $253.9M | $409.0M | $478.6M |
| Deuda Total | 0 | 0 | 0 | $3.3M | $2.6M | $2.4M | $1.4M | $1.2M |
| Deuda Neta | -$3.1M | -$68000 | -$338.5M | -$284.0M | -$201.9M | -$259.4M | -$432.7M | -$504.2M |
| Capital Circulante | $3.0M | -$1.3M | $337.6M | $281.7M | $192.3M | $244.9M | $396.7M | $463.6M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $35.3M | $48.3M | $52.5M | $48.6M |
| Activos Totales | $352.5M | $533.4M | $530.6M | $486.6M |
| Pasivos Totales | $45.0M | $54.9M | $50.2M | $56.0M |
| Patrimonio Neto | $307.5M | $478.6M | $480.5M | $430.6M |
| Deuda Total | $4.5M | $1.2M | $956000 | $660000 |
Flujo de Caja (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$2.2M | -$4.3M | -$22.1M | -$71.1M | -$104.8M | -$96.7M | -$129.5M | -$162.5M |
| Amortizaciones | $8000 | $9033 | $11000 | $1.7M | $1.7M | $377000 | $393000 | $490000 |
| Compensación en Acciones | $1000 | 0 | $3.1M | 0 | 0 | $17.3M | $22.6M | $17.6M |
| Cambio en Capital Circulante | -$110000 | $1.2M | -$1.5M | $2.8M | $3.0M | -$589000 | $9.2M | $2.8M |
| Flujo de Caja Operativo | -$2.2M | -$3.1M | -$19.9M | -$50.7M | -$82.1M | -$83.7M | -$104.4M | -$146.7M |
| Inversiones (CapEx) | 0 | 0 | -$56000 | -$1.6M | -$363000 | 0 | -$159000 | 0 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | -$2.3M | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$2.2M | -$3.1M | -$19.9M | -$52.3M | -$82.4M | -$83.7M | -$104.5M | -$146.7M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$34.5M | -$38.3M | -$46.0M | -$45.9M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$34.5M | -$38.3M | -$46.0M | -$45.9M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $4.2M | $4.3M | 0 | $12.9M |
Crecimiento y Márgenes (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | -96.4% | -412.5% | -221.4% | -47.4% | +7.8% | -34.0% | -25.5% |
| Crecimiento BPA (anual) | | +31.2% | -427.3% | -208.6% | -46.4% | +18.3% | -2.8% | +15.0% |
| Cambio en Acciones (anual) | | +184.9% | -2.1% | +0.5% | +1.2% | +13.1% | +29.8% | +48.1% |
| Crecimiento FCF (anual) | | -41.6% | -546.6% | -162.3% | -57.7% | -1.6% | -24.8% | -40.4% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.15 | $-0.08 | $-0.51 | $-1.32 | $-2.06 | $-1.85 | $-1.78 | $-1.69 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $14.1M | $40.2M | $39.3M | $39.5M | $40.0M | $45.2M | $58.7M | $87.0M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -48.22% |
| Rentabilidad sobre capital invertido | -50.92% |
| Rentabilidad sobre activos | -42.04% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 8.86 |
Ratios Clave (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -306.25 | -445.45 | -82.90 | -5.23 | -0.94 | -6.56 | -2.65 | -13.37 |
| P/VC | -110.04 | -185.80 | 5.59 | 1.30 | 0.50 | 2.50 | 0.84 | 4.55 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |